BerGenBio ASA – Approval and publication of a prospectus supplement

Bergen 19 February 2024 - Reference is made to the stock exchange announcement on 7 December 2023 regarding the approval and publication of a prospectus prepared by BerGenBio ASA (the "Company") for the listing of new shares to be issued by the Company (the "Prospectus").

The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today approved a prospectus supplement dated 19 February 2024 (the "Prospectus Supplement") to the Prospectus. The Prospectus Supplement has been prepared inter alia in connection with the publication by the Company of its results for the fourth quarter of 2023. The information contained in the Prospectus Supplement shall be considered an integral part of, and is to be read together with, the Prospectus. The Prospectus is available, and the Prospectus Supplement will be made available, on the Company's website:

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit

This information is subject to the disclose requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.